{"filings":[{"id":1303116,"accession_number":"0000310764-26-000041","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2026-06-26T19:45:42+00:00","items":["8.01","9.01"],"status":"ready","headline":"Filing contains no material event; XBRL annual report data only","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filing under Items 8.01 and 9.01 provides Inline XBRL for FY 2025 annual report.","No press release, earnings summary, or other narrative disclosure is included.","XBRL tags reference Stryker (SYK) segments, debt, equity, and financial data.","No specific material event or forward-looking guidance is identifiable from the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":554958,"accession_number":"0001193125-26-232643","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2026-05-20T20:21:47+00:00","items":["5.02","9.01"],"status":"ready","headline":"Stryker CAO Berry to retire Sept 1, 2026; Baculik named successor as VP, CAO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William Berry retires as VP, CAO effective Sept 1, 2026; will serve as Advisor to CFO until Aug 15, 2027.","Emily Baculik, currently VP Corporate Controller, becomes CAO on Sept 1, 2026.","Berry's base salary remains $510,000 during advisory period; eligible for 2026 bonus (50% target).","Baculik's base salary rises to $420,000 effective Sept 1, 2026; bonus target 45% of salary.","Recommendation for February 2027 LTI award to Baculik of $400,000 target value (50% options, 50% RSUs)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97895,"accession_number":"0000310764-26-000029","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stryker shareholders elect directors, ratify auditor, approve exec compensation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All ten director nominees elected; Emmanuel P. Maceda had highest dissent with 52.4M against (out of ~290M votes cast).","Ernst & Young LLP ratified as independent auditor for 2026: 284.7M for, 35.3M against, 0.4M abstain.","Advisory 'say-on-pay' resolution approved: 269.4M for, 18.6M against, 2.2M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97894,"accession_number":"0000310764-26-000025","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stryker Q1 net sales $6.0B up 2.6%; adjusted EPS down 8.5% to $2.60; maintains FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $6.0B (+2.6% reported, +2.4% organic); MedSurg/Neuro +5.0%, Orthopaedics +0.1%.","Reported EPS $1.93 (+14.2%); adjusted EPS $2.60 (-8.5%) as adjusted operating margin contracted 180bps to 21.1%.","Maintains FY2026 guidance: organic sales growth 8.0%-9.5%, adjusted EPS $14.90-$15.10.","Company highlights recovery from cyber incident and new Ortho Tech organizational structure combining Mako and instruments."],"consensus_eps_estimate":null,"consensus_eps_actual":1.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":6020000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97893,"accession_number":"0001193125-26-149607","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K/A","filed_at":"2026-04-09T23:59:59+00:00","items":["1.05","7.01"],"status":"ready","headline":"Stryker says cyber incident materially impacted Q1 operations and financial results; full-year guidance unchanged","summary_kind":"llm","event_type":"cyber","confidence":"high","bullets":["Incident identified March 11, 2026; caused business disruptions.","Determined material impact on Q1 2026 operations and financial results.","No material impact expected on full-year 2026 guidance.","Global manufacturing, commercial, ordering, and distribution systems fully restored.","Q1 2026 earnings to be reported on April 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113083,"accession_number":"0001193125-26-118634","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Stryker updates cyber incident: contained, no customer data accessed per Unit 42","summary_kind":"llm","event_type":"cyber","confidence":"high","bullets":["Threat actor used malicious file to hide activity; file not capable of spreading internally or externally.","Investigation has not identified malicious activity directed at customers, suppliers, or partners.","Unit 42 letter confirms no persistent unauthorized access as of March 20, 2026; all IOCs addressed.","Impacted systems being rebuilt or restored; manufacturing ramping as lines come back online.","Company has not yet determined whether incident is reasonably likely to have a material impact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113082,"accession_number":"0001193125-26-104431","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Stryker updates on cyber incident: operations disrupted, patient services unaffected","summary_kind":"llm","event_type":"cyber","confidence":"high","bullets":["Cybersecurity incident affecting Microsoft environment disclosed March 11; CISO provided update March 12.","Order processing, manufacturing, and shipping remain disrupted.","Patient-related services and connected products believed not impacted.","Investigation ongoing; full scope, nature, and financial impact not yet known.","Company does not believe patient data or connected devices were compromised."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113081,"accession_number":"0001193125-26-102460","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Stryker reports global cybersecurity incident affecting Microsoft systems; investigation ongoing","summary_kind":"llm","event_type":"cyber","confidence":"high","bullets":["Incident detected March 11, 2026; global disruption to Microsoft environment; no ransomware or malware; contained.","Operations and corporate functions disrupted; restoration timeline unknown; business continuity measures activated.","Full scope, nature, and financial/operational impact not yet known; investigation continues with external advisors.","Company has not determined if incident will be material; forward-looking statements caution against uncertainty."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113080,"accession_number":"0000310764-26-000006","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stryker reports Q4 2025 sales $7.2B, +11% organic; 2026 outlook 8-9.5% organic growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 reported EPS $2.20 (+56% YoY); adjusted EPS $4.47 (+11.5%).","Full year net sales $25.1B (+11.2% reported); organic growth 10.3%.","MedSurg & Neurotechnology Q4 organic sales +12.6%; Orthopaedics +8.4% organic.","Adjusted operating margin expanded 100 bps to 30.2% in Q4, 26.3% full year.","2026 guidance: organic sales growth 8.0%-9.5%; adjusted EPS $14.90-$15.10."],"consensus_eps_estimate":null,"consensus_eps_actual":8.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":25116000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129489,"accession_number":"0001193125-25-308097","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2025-12-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Stryker appoints Spencer Stiles as President and COO; Crotty promoted to Group President Orthopaedics","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Spencer Stiles appointed President & COO effective Jan 1, 2026; will lead global businesses, strategy, and M&A.","Dylan Crotty promoted to Group President, Orthopaedics, succeeding Stiles, effective same date.","Stiles' base salary increased to $1,000,000; LTIP target value ~$6,000,000 (40% options, 60% PSUs).","Crotty's base salary increased to $700,000; LTIP target value ~$3,000,000 (same equity mix).","Both are 27-year Stryker veterans; no family relationships or material transactions per filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129488,"accession_number":"0000310764-25-000126","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stryker Q3 net sales +10.3% to $6.1B; raises FY 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported EPS $2.22 (+2.8%); adjusted EPS $3.19 (+11.1%).","Organic net sales +9.5% (volume +9.1%, price +0.4%); MedSurg/Neuro +8.4% organic.","Orthopaedics organic +11.4% (ex-divested Spinal +12.5%); adjusted op margin 25.6% (+90 bps).","FY 2025 guidance raised: organic sales growth 9.8%-10.2%, adj EPS $13.50-$13.60."],"consensus_eps_estimate":null,"consensus_eps_actual":6.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":17945000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146050,"accession_number":"0000310764-25-000103","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stryker Q2 2025: net sales $6.0B +11.1%, adj EPS $3.13 +11.4%, raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $6.0B +11.1% reported (+10.2% organic); MedSurg/Neuro +17.3%, Orthopaedics +2.0% (ex-spinal +10.7%).","Reported EPS $2.29 +7.0%; adjusted EPS $3.13 +11.4%. Adj. operating margin 25.7% +110 bps.","FY 2025 guidance raised: organic sales growth 9.5-10.0%, adj EPS $13.40-$13.60.","Tariff impact estimated at ~$175M net, reflecting US-China reduction and proposed US-EU framework."],"consensus_eps_estimate":null,"consensus_eps_actual":3.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":11888000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164354,"accession_number":"0000310764-25-000085","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stryker shareholders approve equity plan amendments, increase share reserves at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved 2011 Long-Term Incentive Plan amendment, increasing shares available and extending duration, effective May 8, 2025.","2011 Performance Incentive Award Plan and 2008 ESPP also amended and restated, approved by shareholders.","All ten director nominees elected; votes ranged from 277M to 291M for, with highest against votes for Kevin Lobo (15.98M) and Ronda Stryker (16.06M).","Ernst & Young ratified as independent auditor for 2025 with 287.65M for, 32.09M against.","Advisory vote on executive compensation approved with 269.9M for, 22.8M against; shareholder proposal on political transparency not presented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164353,"accession_number":"0000310764-25-000072","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stryker Q1 organic sales +10.1%, adj EPS $2.84 (+13.6%), raises FY organic sales growth guidance to 8.5-9.5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported net sales $5.9B (+11.9% YoY); organic net sales +10.1%.","Adjusted EPS $2.84 (+13.6% YoY); reported EPS $1.69 (-17.6%).","Adjusted operating margin improved 100 bps to 22.9% from 21.9%.","FY 2025 organic sales growth guidance raised to 8.5-9.5% from prior.","Adjusted EPS guidance set at $13.20-$13.45, reflecting $200M tariff impact and Inari dilution."],"consensus_eps_estimate":null,"consensus_eps_actual":1.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":5866000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182117,"accession_number":"0001193125-25-039302","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Stryker enters $3.0B revolving credit facility maturing 2030, replacing prior deal","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$3.0B aggregate commitments with maturity February 25, 2030.","Covenant: max leverage ratio 3.75:1; acquisition holiday permits 4.75:1 for four quarters.","Facility fee 7-15 bps on undrawn; interest margins 0-10 bps (Base Rate) to 68-110 bps (Eurocurrency).","Replaces October 2021 credit agreement; terms substantially similar.","Margins based on Issuer Rating; initial Pricing Level 3 (BBB+/Baa1)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182116,"accession_number":"0001193125-25-029187","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["2.01"],"status":"ready","headline":"Stryker completes $4.94B cash acquisition of Inari Medical","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed acquisition of Inari Medical for ~$4.94 billion in cash on Feb 19, 2025.","Merger was effected via merger of Stryker subsidiary with Inari; Inari continues as surviving corporation.","Transaction previously announced under Jan 6, 2025 Merger Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182115,"accession_number":"0001193125-25-023593","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Stryker board member Allan Golston to retire at May 8, 2025 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Allan Golston informed Stryker of his retirement from the Board effective as of the May 8, 2025 Annual Meeting.","Golston will continue serving as a director until the Annual Meeting.","His decision did not involve any disagreement with the company.","No replacement director has been announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182114,"accession_number":"0001193125-25-023587","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Stryker issues $3B in notes; $1.8B earmarked for Inari Medical acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $500M 4.550% notes due 2027, $700M 4.700% notes due 2028, $800M 4.850% notes due 2030, $1B 5.200% notes due 2035.","Net proceeds of ~$2.973B; 2030/2035 notes plus cash to fund Inari Medical tender offer.","2030 and 2035 notes subject to special mandatory redemption at 101% if Inari acquisition not closed by July 7, 2025 (extendable to Oct 6, 2025).","2027 and 2028 notes not subject to special redemption; proceeds for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182113,"accession_number":"0001193125-25-014415","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Stryker CFO Glenn Boehnlein to retire April 1, 2025; Preston Wells promoted as successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Glenn Boehnlein retires after 22 years; will advise CEO through March 2026 at $800k salary plus $215k bonus.","Preston Wells, currently Group CFO Orthopaedics, promoted to CFO effective April 1, 2025.","Wells's new base salary set at $725k with 85% bonus target; LTI target $3M (40% options, 60% PSUs).","Boehnlein's equity awards governed by existing plans; no new equity grants during advisory period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182112,"accession_number":"0000310764-25-000005","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stryker Q4 adjusted EPS up 15.9% to $4.01, organic sales +10.2%; guides 2025 8-9% growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported EPS fell 52.7% to $1.41 due to $818M goodwill/impairment charges on Spine; adjusted EPS rose 15.9% to $4.01.","Organic net sales increased 10.2% in Q4 and full year 2024, driven by 9.1% volume growth and 1.1% price.","Full-year adjusted operating margin expanded 110 bps to 25.3%; reported operating margin was 16.3%.","2025 guidance: organic sales growth 8-9%, adjusted EPS $13.45-$13.70; Inari acquisition expected to close late Feb with ~$590M stub sales."],"consensus_eps_estimate":null,"consensus_eps_actual":7.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":22595000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182111,"accession_number":"0001193125-25-002537","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Stryker to acquire Inari Medical for $80/share cash, ~$4.9B equity value","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Stryker will pay $80 per share in cash for all outstanding Inari shares; total fully diluted equity value ~$4.9B.","Transaction expands Stryker into peripheral vascular segment, adding VTE thrombectomy solutions.","Boards of both companies unanimously approved; transaction expected to close by end of Q1 2025.","Tender offer requires majority share minimum tender, HSR waiting period expiration, and other customary conditions.","Inari (NARI) shareholders will receive $80/share; remaining shares acquired via second-step merger at same price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":198767,"accession_number":"0000310764-24-000113","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stryker Q3 beats: adj EPS $2.87 (+16.7%), sales $5.5B (+11.5% organic), raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported net sales $5.5B, +11.9% reported, +11.5% organic; adjusted EPS $2.87, +16.7%.","Adjusted operating margin expanded 130bps to 24.7%.","MedSurg & Neurotechnology organic sales +12.7%; Orthopaedics & Spine +9.7%.","FY2024 guidance raised: organic sales growth 9.5%-10.0%, adjusted EPS $12.00-$12.10.","CEO cites product innovation and acquisitions as growth drivers."],"consensus_eps_estimate":null,"consensus_eps_actual":6.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":16159000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214798,"accession_number":"0001193125-24-217275","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Stryker completes €1.4B and $1.5B dual-tranche note offerings; proceeds to repay near-term debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued €800M 3.375% notes due 2032, €600M 3.625% notes due 2036, $750M 4.250% notes due 2029, and $750M 4.625% notes due 2034.","Combined net proceeds of ~€1,383M ($1,529M at Aug. 30 FX) from Euro offering and ~$1,482M from USD offering.","Proceeds to repay €500M floating-rate notes due 2024 and €850M 0.250% notes due 2024; balance for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214797,"accession_number":"0000310764-24-000095","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stryker Q2 2024: organic sales +9.0%, adj. EPS $2.81, raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $5.4B (+8.5% reported, +9.0% organic); MedSurg Neuro +9.7% organic, Ortho Spine +8.0% organic.","Reported EPS $2.14 (+10.9% YoY); adjusted EPS $2.81 (+10.6% YoY); adjusted op. margin 24.6% (+30 bps).","FY 2024 organic sales growth guidance raised to 9.0%-10.0%; adjusted EPS guidance $11.90-$12.10.","Adjusted net earnings $1,085M (+11.2%). Guided for modest FX headwind ($0.10-$0.15) on adjusted EPS."],"consensus_eps_estimate":null,"consensus_eps_actual":4.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":10665000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233945,"accession_number":"0000310764-24-000081","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stryker annual meeting results: all directors elected, say-on-pay passed, shareholder proposal rejected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All ten director nominees elected with votes ranging from 291.9M to 304.9M in favor.","Ernst & Young ratified as independent auditor for 2024 (306.6M for, 25.8M against).","Advisory vote on executive compensation approved (277.8M for, 27.3M against).","Shareholder proposal on political spending transparency rejected (113.9M for, 190.3M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233944,"accession_number":"0000310764-24-000062","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stryker Q1 sales $5.2B (+9.7%), organic +10.0%; lifts FY organic growth view to 8.5-9.5%, adj. EPS $11.85-$12.05","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported EPS $2.05 (+33.1%); adjusted EPS $2.50 (+16.8%).","MedSurg & Neurotechnology organic sales +11.6%; Orthopaedics & Spine organic +8.0%.","Reported operating margin 18.5%; adjusted operating margin 21.9% (+80 bps).","FY 2024 organic net sales growth now expected 8.5% to 9.5% (prior range not disclosed).","Adjusted EPS guidance raised to $11.85-$12.05; expects negative FX impact of $0.05-$0.10."],"consensus_eps_estimate":null,"consensus_eps_actual":2.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":5243000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251924,"accession_number":"0000310764-24-000005","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2024-01-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stryker Q4 organic sales up 11.4%; FY23 revenue $20.5B; guides FY24 adj EPS $11.70-$12.00","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 organic net sales growth 11.4% to $5.8B; full year organic growth 11.5% to $20.5B.","Q4 adjusted EPS $3.46 (+15.3% YoY); full year adjusted EPS $10.60 (+13.5%).","Adjusted operating margin expanded 60 bps in Q4 to 27.2%; full year 24.2% (+40 bps).","MedSurg & Neuro organic sales up 11.8% in Q4 and full year; Ortho & Spine up 10.7% Q4, 11.1% FY.","FY2024 outlook: organic sales growth 7.5%-9.0%; adjusted EPS $11.70-$12.00."],"consensus_eps_estimate":null,"consensus_eps_actual":8.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":20498000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269454,"accession_number":"0001193125-23-292590","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Stryker completes €600M offering of 3.375% Notes due 2028","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued €600M aggregate principal of 3.375% Notes due December 11, 2028.","Net proceeds of ~€597M ($649M); intended for general corporate purposes.","Make-whole redemption available prior to Sept 11, 2028; tax redemption at par plus accrued.","Change-of-control with rating downgrade triggers offer at 101% of principal plus accrued interest.","Underwriters: Barclays, Goldman Sachs, Mizuho, Wells Fargo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269453,"accession_number":"0001193125-23-291773","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2023-12-08T23:59:59+00:00","items":["1.01","2.03","5.02","9.01"],"status":"ready","headline":"Stryker issues $600M 4.850% Notes due Dec 2028; net proceeds ~$594M for general purposes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$600M aggregate principal of 4.850% Notes maturing Dec 8, 2028; interest payable semiannually June 8 and Dec 8 starting June 8, 2024.","Net proceeds of ~$594M after underwriting discount and expenses; used for general corporate purposes.","Notes redeemable at make-whole premium prior to Nov 8, 2028; change of control put at 101% if downgraded below investment grade.","Director Dr. Srikant Datar to retire from Board effective at annual meeting expected May 9, 2024; no disagreement with company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269452,"accession_number":"0000310764-23-000114","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stryker Q3 net sales $4.9B (+9.6%), adjusted EPS $2.46 (+16.0%), raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported net sales $4.9B, +9.6% YoY; organic net sales +9.2%.","Adjusted EPS of $2.46 increased 16.0% year-over-year; reported EPS $1.80 decreased 15.9%.","Adjusted operating margin 23.4% (+110 bps); MedSurg/Neuro organic +10.1%, Ortho/Spine +8.0%.","FY2023 organic net sales growth guidance raised to 10.0%-10.5%; adjusted EPS guidance to $10.35-$10.45."],"consensus_eps_estimate":null,"consensus_eps_actual":5.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":14683000000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286423,"accession_number":"0000310764-23-000104","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stryker Q2 2023: Net sales +11.2% to $5.0B; adj. EPS $2.54; raises FY organic growth outlook to 9.5%-10.5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $5.0B, +11.2% reported, +11.9% organic; adj. EPS $2.54 (+12.9%).","MedSurg & Neurotechnology $2.9B (+12.9% organic); Orthopaedics & Spine $2.1B (+10.6% organic).","Reported op margin 19.3%; adjusted op margin 24.3% (up 60bps).","FY2023 organic sales growth guidance raised to 9.5%-10.5%; adj EPS guidance $10.25-$10.45."],"consensus_eps_estimate":null,"consensus_eps_actual":3.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":9774000000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306314,"accession_number":"0001193125-23-169034","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Stryker amends credit agreement to transition from LIBOR to SOFR benchmarks","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amendment No. 1 to Oct 2021 Credit Agreement replaces LIBOR with SOFR-based rates and adds conforming changes.","Effective June 15, 2023; existing LIBOR loans convert to Term SOFR at end of current interest periods.","No changes to loan amounts, covenants, or pricing; conditions of effectiveness satisfied."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306313,"accession_number":"0000310764-23-000089","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stryker shareholders elect all directors, approve say-on-pay, reject political disclosure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All ten directors elected with majority support; Rajeev Suri received highest votes (312.1M), Kevin Lobo lowest (302.4M).","Appointment of Ernst & Young LLP as auditor ratified with 316.7M votes for, 23.6M against.","Advisory vote on executive compensation approved with 275.5M for, 39.7M against.","Frequency of future say-on-pay votes set to every year with 311.6M votes for one year.","Shareholder proposal on political disclosure rejected with 115.6M for, 198.4M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306312,"accession_number":"0000310764-23-000065","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stryker Q1 organic sales +13.6%; raises FY growth guidance to 8-9%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported net sales $4.8B, +11.8% reported, +13.6% organic; MedSurg/Neuro +12.4%, Ortho+Spine +15.2%.","Adjusted EPS $2.14 (+8.6% YoY); reported EPS $1.54 (+83.3% on lower prior year).","Adjusted operating margin 21.1% contracted 70 bps YoY.","Raises FY 2023 organic net sales growth guidance to 8.0-9.0% (from prior implied).","Guides FY 2023 adjusted EPS to $10.05-$10.25."],"consensus_eps_estimate":null,"consensus_eps_actual":1.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":4778000000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325478,"accession_number":"0000310764-23-000005","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2023-01-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stryker Q4 organic sales +13.2%, adj. EPS $3.00; FY23 adj. EPS guide $9.85-10.15","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 reported sales $5.2B (+10.7% YoY); organic sales +13.2% driven by MedSurg and Neurotechnology (+16.9% organic).","Q4 reported EPS $1.47 (-15.0%); adjusted EPS $3.00 (+10.7%) – includes $216M goodwill impairment in Spine.","Full-year sales $18.4B (+7.8% reported); organic sales +9.7%; adjusted EPS $9.34 (+2.8%).","2023 outlook: organic sales growth 7.0-8.5%; adjusted EPS $9.85-$10.15.","Adjusted operating margin contracted 70 bps in Q4 to 26.6% and 180 bps for FY to 23.8%."],"consensus_eps_estimate":null,"consensus_eps_actual":6.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":18449000000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343223,"accession_number":"0000310764-22-000113","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2022-11-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Stryker amends bylaws to adopt universal proxy card rules","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Board adopted amended bylaws effective November 1, 2022.","Amendments incorporate SEC Rule 14a-19 universal proxy requirements for director nominations.","Other clarifying and conforming changes made to the bylaws.","No financial impact or operational change from the amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343222,"accession_number":"0000310764-22-000103","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2022-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stryker Q3 organic sales +9.9% to $4.5B; adj EPS $2.12 -3.6%; guides FY adj EPS $9.15-$9.25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $4.5B (+7.7% reported, +9.9% organic); MedSurg & Neuro +10.8% organic, Ortho & Spine +8.7%.","Reported EPS $2.14 (+87.7%); adjusted EPS $2.12 (-3.6%); adjusted operating margin 22.3% (-310 bps).","FY 2022 organic net sales growth guidance raised to 8.5%-9.0%; currency to hit sales ~4% and adj EPS $0.35-$0.40.","Adjusted EPS guidance narrowed to $9.15-$9.25 from prior view, citing inflation and FX headwinds.","CEO cites strong capital equipment order book and sales momentum despite product shortages."],"consensus_eps_estimate":null,"consensus_eps_actual":4.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":13247000000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359772,"accession_number":"0000310764-22-000089","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2022-07-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stryker Q2 organic sales +6.1% to $4.5B; lowers FY adjusted EPS guidance to $9.30-$9.50","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported net sales of $4.5B (+4.6% YoY); organic net sales +6.1%.","Reported EPS $1.72 (+11%); adjusted EPS of $2.25 flat YoY.","MedSurg & Neurotechnology organic sales +7.9%; Orthopaedics & Spine organic +3.9%.","Adjusted operating margin contracted 220 bps to 23.7%; FY22 organic sales guidance raised to 8-9%."],"consensus_eps_estimate":null,"consensus_eps_actual":2.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":8768000000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378602,"accession_number":"0000310764-22-000081","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stryker shareholders elect all 10 director nominees, ratify Ernst & Young","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 director nominees elected with > 94% of votes cast for each; Kevin Lobo received lowest support at 95.5%.","Ernst & Young ratified as auditor for 2022 with 93.9% of votes for.","Advisory say-on-pay resolution approved with 90.6% of votes cast in favor.","Shareholder proposal on proxy access terms rejected with only 19.6% support.","Broker non-votes of 25.9M shares on all director and advisory proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378601,"accession_number":"0000310764-22-000069","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Stryker appoints Sherilyn S. McCoy as Lead Independent Director, effective May 4, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Allan C. Golston steps down as Lead Independent Director after six years; Sherilyn S. McCoy succeeds.","Mary K. Brainerd replaces McCoy as Chair of Governance and Nominating Committee.","Golston remains Chair of Compensation Committee; other committee assignments updated.","No CEO change; Kevin A. Lobo continues as Chair and CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378600,"accession_number":"0000310764-22-000060","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2022-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stryker Q1 sales up 9.2% organic to $4.3B; lowers adjusted EPS guidance to lower end of $9.60-$10.00","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported net sales $4.3B (+8.1%), organic +9.2%; MedSurg +10.8%, Orthopaedics and Spine +7.2%.","Adjusted EPS $1.97 (+2.1%); adjusted operating margin 21.8% contracted 170 bps.","Revised 2022 outlook: organic sales growth at high end of 6-8%; adjusted EPS at lower end of $9.60-$10.00.","Expects supply chain shortages and inflation to persist; currency headwind ~1.2% on sales, ~$0.10-$0.15 on adj. EPS."],"consensus_eps_estimate":null,"consensus_eps_actual":0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":4275000000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396874,"accession_number":"0000310764-22-000035","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2022-02-25T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Stryker enters $1.5B term loan agreement maturing 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed full $1.5B on Feb 22, 2022; maturity Feb 22, 2025.","Interest at Adjusted Term SOFR plus margin of 62.5-82.5 bps per credit rating.","Leverage ratio covenant max 3.75:1; acquisition holiday allows 4.75:1 for four quarters.","Joint lead arrangers: Wells Fargo, BofA, Citibank, BNP Paribas, Mizuho, U.S. Bank."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396873,"accession_number":"0001193125-22-050010","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2022-02-23T23:59:59+00:00","items":["2.01"],"status":"ready","headline":"Stryker completes acquisition of Vocera Communications for ~$3.1B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Completed acquisition of Vocera Communications on Feb 23, 2022 for total consideration of ~$3.1B including repayment of convertible notes.","Merger structured under Section 251(h) of Delaware law; Vocera continues as surviving subsidiary of Stryker.","Acquisition originally announced Jan 6, 2022; Merger Agreement filed as Exhibit 2.1 to Stryker's Jan 11, 2022 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396872,"accession_number":"0000310764-22-000008","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2022-01-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stryker Q4 sales $4.7B (+10.3%), FY21 adj. EPS $9.09 (+22.3%); forecasts FY22 adj. EPS $9.60-10.00","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $4.7B, +10.3% YoY; organic +9.0% vs 2020, +6.2% vs 2019.","Q4 reported EPS $1.73 (+16.1%); adjusted EPS $2.71 (-3.6%) year-over-year.","Full-year net sales $17.1B, +19.2% YoY; reported EPS $5.21 (+24.0%); adjusted EPS $9.09 (+22.3%).","MedSurg & Neurotech FY organic sales +13.1%; Orthopaedics & Spine FY organic +12.0%.","2022 outlook: organic sales growth 6%-8%; adjusted EPS $9.60-$10.00; expects ~1% price headwind."],"consensus_eps_estimate":null,"consensus_eps_actual":5.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":17108000000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396871,"accession_number":"0000310764-22-000003","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2022-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Stryker realigns into MedSurg/Neurotechnology and Orthopaedics/Spine segments effective Dec 31, 2021","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Segments reflect new internal structure after COO transition; Pierce leads MedSurg/Neuro, Stiles leads Ortho/Spine.","FY 2021 recast sales: MedSurg/Neuro $8,345M, Ortho/Spine $6,006M, total $14,351M.","Q4 2021 recast sales: MedSurg/Neuro $2,429M, Ortho/Spine $1,833M, total $4,262M.","Exhibit 99.1 provides recast historical sales for 2019, 2020, and full-year 2021.","Change aligns with previously announced management responsibilities transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396870,"accession_number":"0001193125-22-006816","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2022-01-11T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Stryker agrees to acquire Vocera Communications for $79.25 per share in cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Stryker to acquire Vocera Communications for $79.25 per share in cash via tender offer and merger.","Vocera board unanimously recommends that stockholders tender shares into the offer.","Offer subject to majority tender, HSR clearance, absence of material adverse effect and other conditions.","Termination fee of $108.7 million payable by Vocera under specified circumstances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396869,"accession_number":"0001193125-22-000261","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2022-01-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Stryker to refund $1.85/share Dutch withholding tax to former Wright shareholders after tax proposal not enacted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$1.85 per share Dutch dividend withholding tax was withheld from Wright shareholders exchanging shares for cash in the merger.","Dutch legislative proposal on conditional final dividend withholding tax not enacted by January 1, 2022, so no remittance to Dutch authorities.","Stryker instructed the paying agent to return the $1.85 per share to each former Wright shareholder from whom it was withheld.","Payment expected promptly; no refund for shares purchased in Stryker's tender offer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":415830,"accession_number":"0000310764-21-000144","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2021-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stryker Q3: adj EPS $2.20 (+2.8%); organic sales +4.5%; China impairment $105M; guidance revised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $4.2B, +11.3% vs 2020; organic net sales +4.5% vs 2020 and +8.4% vs 2019.","Reported EPS $1.14 (down 30.1%); adjusted EPS $2.20 (up 2.8%) due to $105M impairment.","$105M impairment for China trauma/joint replacement VBP price reductions impacting Orthopaedics.","2021 outlook: organic sales growth 7%-8% from 2019; adj EPS $9.08-$9.15."],"consensus_eps_estimate":null,"consensus_eps_actual":3.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":12407000000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":433435,"accession_number":"0000310764-21-000123","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2021-08-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Stryker announces retirement of President and COO Timothy Scannell, leadership changes","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["President and COO Timothy J. Scannell to retire on March 31, 2023; will serve as Advisor to CEO from Oct 1, 2021.","J. Andrew Pierce, Group President MedSurg & Neuro, and Spencer S. Stiles, Group President Ortho & Spine, to assume Scannell's responsibilities.","Kevin A. Lobo, Chair & CEO, will additionally become President of Stryker effective Oct 1, 2021.","Scannell entered a letter agreement with base salary of $825,000 and bonus eligibility through retirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":433434,"accession_number":"0000310764-21-000108","cik":310764,"company_name":"STRYKER CORP","ticker":"SYK","form_type":"8-K","filed_at":"2021-07-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Stryker Q2 net sales $4.3B (+55% YoY), raises FY2021 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported net sales $4.3B, +55.4% from 2020 and +17.6% from 2019; organic net sales +42.9% from 2020.","Reported EPS $1.55; adjusted EPS $2.25 (up from $0.64 in Q2 2020).","Adjusted operating income margin 25.9% vs reported 17.0%.","Orthopaedics $1.6B (+82.3%), MedSurg $1.7B (+32.3%), Neuro/Spine $0.9B (+66.9%) from 2020.","Raises FY2021 outlook: organic net sales growth 9-10% from 2019; adj. EPS $9.25-$9.40."],"consensus_eps_estimate":null,"consensus_eps_actual":2.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":8247000000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":117285387332.06741,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-07-27T23:59:59+00:00|433434"}